Healthy Relationships and Economic Pathways

NCT03519191 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-09-13

No results posted yet for this study

Summary

The California Adolescent Health Collaborative (CAHC) brings together multiple nonprofit organizations in California's Central Valley to implement the Healthy Relationships and Economic Pathways (H-REP) program, which aims to increase and promote healthy relationships and stability among youth between the ages of 14 and 24.

Conditions

  • Adolescent Relationship Abuse
  • Sexually Transmitted Infections
  • Pregnancy (Unwanted)
  • Violence
  • Intentional Injury

Interventions

BEHAVIORAL

Healthy Relationships Education (HRE)

Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.

BEHAVIORAL

HRE+Technology Bootcamp

HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.

Sponsors & Collaborators

  • American Institutes for Research

    collaborator OTHER
  • Public Health Institute, California

    lead OTHER

Principal Investigators

  • Alison Chopel, DrPH · Public Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-07-01
Completion
2018-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03519191 on ClinicalTrials.gov